The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Oxaliplatin, irinotecan, bevacizumab followed by docetaxel, bevacizumab in inoperable gastric cancer: First efficacy results of a multicenter phase II trial (AGMT Gastric-3) of the Arbeitsgemeinschaft Medikamentöse Tumortherapie.
Ewald Woell
Honoraria - Pfizer; Roche; Sanofi
Other Remuneration - Pfizer; Roche; Sanofi
Josef Thaler
No relevant relationships to disclose
Felix Keil
No relevant relationships to disclose
Wolfgang Eisterer
No relevant relationships to disclose
Michael A. Fridrik
Consultant or Advisory Role - Pfizer; Roche; Sanofi
Honoraria - Pfizer; Roche; Sanofi
Research Funding - Pfizer; Roche; Sanofi
Other Remuneration - Pfizer; Roche; Sanofi
Birgit Gruenberger
No relevant relationships to disclose
Michael Hejna
No relevant relationships to disclose
Franz Romeder
No relevant relationships to disclose
Richard Greil
No relevant relationships to disclose